Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

The Drugs industry as a whole closed the day down 0.4% versus the S&P 500, which was down 0.5%. Laggards within the Drugs industry included ImmuCell ( ICCC), down 3.6%, Oragenics ( OGEN), down 7.6%, China Pharma ( CPHI), down 3.6%, Ruthigen ( RTGN), down 1.5% and Cellectar Biosciences ( CLRB), down 4.0%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Ruthigen ( RTGN) is one of the companies that pushed the Drugs industry lower today. Ruthigen was down $0.06 (1.5%) to $3.87 on light volume. Throughout the day, 2,504 shares of Ruthigen exchanged hands as compared to its average daily volume of 13,000 shares. The stock ranged in price between $3.87-$3.91 after having opened the day at $3.91 as compared to the previous trading day's close of $3.93.

Ruthigen has a market cap of $18.6 million and is part of the health care sector. Shares are up 12.3% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Ruthigen a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, China Pharma ( CPHI) was down $0.02 (3.6%) to $0.40 on light volume. Throughout the day, 63,312 shares of China Pharma exchanged hands as compared to its average daily volume of 100,800 shares. The stock ranged in price between $0.38-$0.44 after having opened the day at $0.44 as compared to the previous trading day's close of $0.42.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. China Pharma has a market cap of $18.0 million and is part of the health care sector. Shares are up 38.3% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates China Pharma as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and poor profit margins.

Highlights from TheStreet Ratings analysis on CPHI go as follows:

  • CHINA PHARMA HOLDINGS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, CHINA PHARMA HOLDINGS INC swung to a loss, reporting -$0.45 versus $0.10 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 174.9% when compared to the same quarter one year ago, falling from -$2.30 million to -$6.33 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, CHINA PHARMA HOLDINGS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to $0.18 million or 71.56% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The gross profit margin for CHINA PHARMA HOLDINGS INC is currently lower than what is desirable, coming in at 34.60%. Regardless of CPHI's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, CPHI's net profit margin of -113.66% significantly underperformed when compared to the industry average.

You can view the full analysis from the report here: China Pharma Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Oragenics ( OGEN) was another company that pushed the Drugs industry lower today. Oragenics was down $0.08 (7.6%) to $0.97 on average volume. Throughout the day, 30,659 shares of Oragenics exchanged hands as compared to its average daily volume of 36,900 shares. The stock ranged in price between $0.93-$1.03 after having opened the day at $1.03 as compared to the previous trading day's close of $1.05.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $41.6 million and is part of the health care sector. Shares are up 29.3% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Oragenics a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Oragenics as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • OGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 66.96%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 89.0% when compared to the same quarter one year prior, rising from -$9.33 million to -$1.03 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The revenue fell significantly faster than the industry average of 36.4%. Since the same quarter one year prior, revenues fell by 20.6%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • The gross profit margin for ORAGENICS INC is rather high; currently it is at 66.67%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -512.43% is in-line with the industry average.

You can view the full analysis from the report here: Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.